All In Biotech

Drug Trial Radar · NCT07545395

Safety of KN057 Prophylaxis in Patients With Haemophilia A or B

An Open-label Study to Evaluate the Safety of KN057 Long-term Prophylaxis in Patients With Hemophilia A or Hemophilia B With or Without Inhibitors

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Mar 13, 2026

Primary completion

Dec 30, 2027

Study completion Mar 30, 2028

Sponsor

Lead sponsor
Suzhou Alphamab Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purposes of this open-label, multicenter III clinical trial are to evaluate the safety and efficacy of long-term preventive treatment with KN057 in Haemophilia A or B patients with or without inhibitors, and to assess the pharmacokinetic characteristics of the new and old processes KN057. The participants in Part PK will be randomly assigned to Old process Group or New process Group in a 1:1 ratio. The participants in Old process Group will receive old process KN057 prophylaxis for the first 26 weeks and new process KN057 prophylaxis for the following 26 weeks. The participants in New process Group will receive new process KN057 prophylaxis for both the first 26 weeks and the last 26 weeks. The participants in Part non-PK will be non-randomized and treated with new process KN057 for 52 weeks prophylaxis after enrollment. Priority screening and enrollment of participants who have participated in the KN057-A-301 or KN057-A-302 study.

Conditions

  • Hemophilia A or B

Interventions

  • KN057Drug

    KN057 will be administered subcutaneously once a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of TEAE.Time frame: Up to 12/26/56 weeks.
  2. Incidence of TEAE related to the experimental drug.Time frame: Up to 12/26/56 weeks.
  3. Incidence of SAE.Time frame: Up to 12/26/56 weeks.
  4. Incidence of thromboembolic events.Time frame: Up to 12/26/56 weeks.
  5. Incidence of TMA and DIC.Time frame: Up to 12/26/56 weeks.
  6. Incidence of hypersensitivity type reactions.Time frame: Up 12/26/56 weeks.
  7. Incidence of injection site reactions.Time frame: Up to 12/26/56 weeks.
  8. Incidence of clinically significant laboratory value abnormalities.Time frame: Up to 12/26/56 weeks.
  9. Number of participants with clinically significant changes from baseline in electrocardiograms.Time frame: Up to 12/26/56 weeks.
  10. Number of participants with clinically significant changes from baseline in vital signs.Time frame: Up to 12/26/56 weeks.
  11. Number of participants with clinically significant changes from baseline in physical exam.Time frame: Up to 12/26/56 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.